Osteoprotegerin predicts long-term outcome in patients with st-segment elevation myocardial infarction treated with primary percutaneous coronary intervention

Cardiology (Switzerland)

Volumn 123, Issue 1, 2012, Pages 31-38

  Pedersen, Sune ^a   Mogelvang, Rasmus ^d   Bjerre, Mette ^c   Frystyk, Jan ^c   Flyvbjerg, Allan ^c   Galatius, Soren ^a   Sørensen, Tor Biering ^a   Iversen, Allan ^a   Hvelplund, Anders ^a   Jensen, Jan S ^a,b  

^a Mental Health Services CPH   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d HOLBÆK HOSPITAL   (Denmark)

Author keywords

Inflammation; Myocardial infarction; Osteoprotegerin; Percutaneous coronary intervention; ST segment elevation; STEMI

Indexed keywords

C REACTIVE PROTEIN; OSTEOPROTEGERIN; TROPONIN I;

ADULT; AGED; ARTICLE; CORRELATIONAL STUDY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OSTEOPROTEGERIN; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84865842304     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000339880     Document Type: Article

References (37)

1. Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbæk H, Thayssen P, Abildgaard U, Pedersen F, Madsen JK, Grande P, Villadsen AB, Krusell LR, Haghfelt T, Lomholt P, Husted SE, Vigholt E, Kjærgard HK, Mortensen LS: A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003; 349: 733-742.
2. Keeley EC, Hillis LD: Primary PCI for myocardial infarction with ST-segment elevation. N Engl J Med 2007; 356: 47-54.
3. Keeley EC, Boura JA, Grines CL: Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361: 13-20.
4. Scirica BM: Acute coronary syndrome: emerging tools for diagnosis and risk assessment. J Am Coll Cardiol 2010; 55: 1403-1415.
5. Gupta S, Drazner MH, de Lemos JA: Newer biomarkers in heart failure. Heart Fail Clin 2009; 5: 579-588.
6. Niccoli G, Montone RA, Ferrante G, Crea F: The evolving role of inflammatory biomarkers in risk assessment after stent implantation. J Am Coll Cardiol 2010; 56: 1783-1793.
7. Jeong YH, Lee SW, Lee CW, Hong MK, Kim JJ, Park SW, Park SJ, Park DW, Kim YH: Biomarkers on admission for the prediction of cardiovascular events after primary stenting in patients with ST-elevation myocardial infarction. Clin Cardiol 2008; 31: 572-579.
8. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
9. Libby P, Ridker PM, Hansson GK: Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54: 2129-2138.
10. Yellon DM, Hausenloy DJ: Myocardial reperfusion injury. N Engl J Med 2007; 357: 1121-1135.
11. Arumugam TV, Magnus T, Woodruff TM, Proctor LM, Shiels IA, Taylor SM: Complement mediators in ischemia-reperfusion injury. Clin Chim Acta 2006; 374: 33-45.
12. Flyvbjerg A: Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily. Nat Rev Endocrinol 2010; 6: 94-101.
13. Reid P, Holen I: Pathophysiological roles of osteoprotegerin (OPG). Eur J Cell Biol 2009; 88: 1-17.
14. Abedin M, Omland T, Ueland T, Khera A, Aukrust P, Murphy SA, Jain T, Gruntmanis U, McGuire DK, de Lemos JA: Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol 2007; 99: 513-518.
15. Omland T, Drazner MH, Ueland T, Abedin M, Murphy SA, Aukrust P, de Lemos JA: Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension 2007; 49: 1392-1398.
16. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, Santer P, Smolen J, Poewe W, Willeit J: Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004; 109: 2175-2180.
17. Semb AG, Ueland T, Aukrust P, Wareham NJ, Luben R, Gullestad L, Kastelein JJ, Khaw KT, Boekholdt SM: Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003. Arterioscler Thromb Vasc Biol 2009; 29: 975-980.
18. Ueland T, Jemtland R, Godang K, Kjekshus J, Hognestad A, Omland T, Squire IB, Gullestad L, Bollerslev J, Dickstein K, Aukrust P: Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 2004; 44: 1970-1976.
19. Omland T, Ueland T, Jansson AM, Persson A, Karlsson T, Smith C, Herlitz J, Aukrust P, Hartford M, Caidahl K: Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 2008; 51: 627-633.
20. Andersen GO, Knudsen EC, Aukrust P, Yndestad A, Oie E, Muller C, Seljeflot I, Ueland T: Elevated serum osteoprotegerin levels measured early after acute ST-elevation myocardial infarction predict final infarct size. Heart 2011; 97: 460-465.
21. Tsirpanlis G: Is inflammation the link between atherosclerosis and vascular calcification in chronic kidney disease? Blood Purif 2007; 25: 179-182.
22. Shaker OG, El-Shehaby A, Nabih M: Possible role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as markers of plaque instability in coronary artery disease. Angiology 2010; 61: 756-762.
23. Newby AC: Metalloproteinases and vulnerable atherosclerotic plaques. Trends Cardiovasc Med 2007; 17: 253-258.
24. Molloy KJ, Thompson MM, Jones JL, Schwalbe EC, Bell PR, Naylor AR, Loftus IM: Unstable carotid plaques exhibit raised matrix metalloproteinase-8 activity. Circulation 2004; 110: 337-343.
25. Montecucco F, Steffens S, Mach F: The immune response is involved in atherosclerotic plaque calcification: could the RANKL/RANK/OPG system be a marker of plaque instability? Clin Dev Immunol 2007; 2007: 75805.
26. Sandberg WJ, Yndestad A, Oie E, Smith C, Ueland T, Ovchinnikova O, Robertson AK, Muller F, Semb AG, Scholz H, Andreassen AK, Gullestad L, Damas JK, Froland SS, Hansson GK, Halvorsen B, Aukrust P: Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol 2006; 26: 857-863.
27. Arslan F, de Kleijn DP, Timmers L, Doevendans PA, Pasterkamp G: Bridging innate immunity and myocardial ischemia/reperfusion injury: the search for therapeutic targets. Curr Pharm Des 2008; 14: 1205-1216.
28. Rasmussen LM, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A: Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol 2006; 154: 75-81.
29. Madsen M, Davidsen M, Rasmussen S, Abildstrom SZ, Osler M: The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol 2003; 56: 124-130.
30. Nybo M, Rasmussen LM: The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. Eur J Endocrinol 2008; 159: 603-608.
31. Jono S, Otsuki S, Higashikuni Y, Shioi A, Mori K, Hara K, Hashimoto H, Ikari Y: Serum osteoprotegerin levels and long-term prognosis in subjects with stable coronary artery disease. J Thromb Haemost 2010; 8: 1170-1175.
32. Sherwood MW, Morrow DA, Scirica BM, Jiang S, Bode C, Rifai N, Gerszten RE, Gibson CM, Cannon CP, Braunwald E, Sabatine MS: Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLopidogrel as Adjunctive ReperfusIon TherapY (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28. Am Heart J 2010; 159: 964-971.
33. Chiostri M, Valente S, Crudeli E, Giglioli C, Gensini GF: A new post-PCI scoring system for in-hospital mortality in STEMI patients. J Cardiovasc Med (Hagerstown) 2010; 11: 733-738.
34. Napan S, Kashinath RC, Kadri S, Orig MN, Khadra S: Prognostic significance of preprocedural troponin-I in patients with non-ST elevation acute coronary syndromes undergoing percutaneous coronary intervention. Coron Artery Dis 2010; 21: 261-265.
35. Jeong YH, Lee SW, Lee CW, Hong MK, Kim JJ, Park SW, Park SJ, Park DW, Kim YH: Biomarkers on admission for the prediction of cardiovascular events after primary stenting in patients with ST-elevation myocardial infarction. Clin Cardiol 2008; 31: 572-579.
36. Byrne RA, Ndrepepa G, Braun S, Tiroch K, Mehilli J, Schulz S, Schomig A, Kastrati A: Peak cardiac troponin-T level, scintigraphic myocardial infarct size and one-year prognosis in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 2010; 106: 1212-1217.
37. Gibbons RJ, Valeti US, Araoz PA, Jaffe AS: The quantification of infarct size. J Am Coll Cardiol 2004; 44: 1533-1542.